Photostability and Light Degradation: An Instruction, Not a Measurement
Every research peptide sold in the United States arrives with some version of the same sentence: store away from light. Ours say it too. It appears on the product page, it appears in the handling notes, and it is repeated so uniformly across the category that it reads like a specification.
It is not a specification. It is a precaution, and there is a large and specific difference between the two. A specification is a number that something was measured against. “Protect from light” is a habit inherited from pharmaceutical packaging copy, carried forward by suppliers who have never run the test that would justify it — and, to be equally direct, by us. Not one certificate of analysis in this category, ours included, reports a photostability result. The guideline that defines how such a result would be produced has existed since 1996 and is unusually precise about it.
What ICH Q1B actually requires
ICH Q1B is the harmonized photostability guideline, and it is worth reading because it demonstrates how much apparatus sits behind the phrase “light stable.”
The guideline offers two light-source options. Option 1 is any source designed to produce an output similar to the D65/ID65 emission standard — an artificial daylight fluorescent lamp with combined visible and ultraviolet output, or a xenon or metal halide lamp, with filters permitted to eliminate radiation below 320 nm. Option 2 is a dual exposure: a cool white fluorescent lamp meeting ISO 10977, plus a near-UV fluorescent lamp “having a spectral distribution from 320 nm to 400 nm with a maximum energy emission between 350 nm and 370 nm.”
The exposure itself is quantified. Samples “should be exposed to light providing an overall illumination of not less than 1.2 million lux hours and an integrated near ultraviolet energy of not less than 200 watt hours/square meter.” Both criteria must be met. Illumination alone does not satisfy the guideline, because visible light and near-UV drive different chemistry.
Two design details are what make the result interpretable rather than merely dramatic. First, dark controls: samples wrapped in aluminum foil are exposed alongside the test samples, so that any change attributable to the chamber’s temperature rather than its light can be subtracted. Without a foil control, a photostability study is a warm-cupboard study with a lamp in it. Second, chemical actinometry: a 2% quinine monohydrochloride dihydrate solution serves as an independent check that the chamber delivered what the sensor claimed, requiring a change in absorbance of at least 0.9 under Option 1 in sealed ampoules, or at least 0.5 under Option 2 in quartz cells.
Q1B also draws the same line Q1A draws between forced degradation and confirmatory study. Forced photodegradation deliberately over-exposes material to establish photosensitivity and to validate that the analytical method can see photoproducts; its results “don’t establish quantitative limits for change.” The confirmatory study is the one that supports a labeling statement, and it proceeds through a defined packaging sequence — directly exposed material, then the immediate pack, then the marketing pack — continuing until the product is demonstrably protected.
That sequence is the part worth holding on to. A photostability claim is always a claim about a material in a container, never about a molecule in the abstract.
What light actually does to a peptide
The mechanism is well characterized. Hipper, Blech, Hinderberger, Garidel and Kaiser reviewed photo-oxidation of therapeutic protein formulations in Pharmaceutics in 2022, and their account divides the chemistry into two pathways. In the Type I pathway a photosensitizer absorbs light, crosses to a triplet state, and transfers electrons to substrates, generating radicals and radical ions that propagate. In the Type II pathway the excited triplet sensitizer transfers energy to molecular oxygen, producing singlet oxygen, which oxidizes directly.
The review’s most useful observation for anyone storing peptides is about wavelength, and it cuts against intuition. The residues usually blamed for photosensitivity — tryptophan and tyrosine — absorb only in UV-C (200–280 nm) and UV-B (280–315 nm). Ordinary environments do not supply those wavelengths in quantity: room lighting runs from around 1,000 lux, direct sunlight reaches roughly 130,000 lux, and both are dominated by UV-A (315–400 nm) and visible light, while window glass and pharmaceutical container materials absorb the shorter wavelengths. The consequence the authors draw is that “most photo-oxidation processes observed in therapeutic protein formulations are not based on proteinogenic sensitizer.” The reaction is usually started by something else in the vial — a buffer component, a surfactant, a trace metal — which absorbs the light the peptide cannot.
That is a genuinely different failure model from thermal degradation, and it explains why a photostability result cannot be inferred from a purity number, a water content, or a storage temperature. It depends on what else is present.
The solid state is doing most of the protecting
There is a recent study that quantifies exactly this for a lyophilized peptide product, and it is directly on point. Pritts, Ortega-Rodriguez and Rao, publishing in Pharmaceutical Research in 2025, exposed somatropin — a therapeutic growth hormone — to ICH Q1B conditions in three presentations: lyophilized, reconstituted at 5 mg/mL, and diluted to 0.5 mg/mL. They then measured the same quality attributes across all three.
The gap between the solid and the solutions is large and consistent. High molecular weight species by size-exclusion chromatography rose by 0.4% in the lyophilized material, 2.7% reconstituted, and 4.7% diluted. Acidic charge variants by imaged capillary isoelectric focusing rose by 2.8%, 7.8% and 6.2% respectively. Methionine-14 oxidation by LC–MS/MS peptide mapping rose by 2.3% lyophilized against 7.4% reconstituted. Micro-flow imaging found no significant change in particle counts in any presentation. The authors’ conclusion is stated plainly: light exposure altered quality attributes “with more pronounced effects on liquid presentations.”
The practical reading is straightforward. A sealed lyophilized cake is not immune to light, but it is roughly an order of magnitude less sensitive than the same material in solution, because photo-oxidation chemistry needs mobility and dissolved oxygen and the dry cake supplies little of either. The moment a vial is reconstituted, the light sensitivity of the contents changes category. Every “protect from light” instruction in this industry is written on the dry powder and then quietly assumed to cover the solution, which is where it matters most and where nobody has measured it.
The one case in our catalog where color tells you something
Most certificates in this category record appearance as “white lyophilized powder.” One of ours does not. The batch certificate for the GHK-Cu 50MG reference material — report DBAV-GHK-Cu-50-062226, lot 5816, received 25 June 2026, tested 7 July, reported 8 July — records a mass of 53.18 mg and purity of 99.56% by HPLC-UV at 214 nm, and records the appearance as blue powder.
That color is not cosmetic. It is the visible absorption of a copper(II) complex, and visible absorption is the precondition for visible-light photochemistry. A material that absorbs in the visible is a material for which the ordinary room-light exposure the Hipper review describes is chemically relevant, not merely notional. This is the one compound in our catalog where the standing precaution has a mechanism behind it, and it is the one product page where we say so explicitly rather than relying on boilerplate.
It is also the certificate that most conspicuously lacks a photostability row — along with every other certificate we hold. We think that asymmetry is worth stating in public rather than papering over: the product page names a photosensitivity that the accompanying certificate does not test for.
What a US laboratory can reasonably do about it
Three things, none of which require trusting a supplier’s adjectives.
Keep the vial in its secondary carton until use. Q1B’s own packaging sequence exists because the outer pack is frequently what does the protecting, and a carton costs nothing.
Treat the reconstituted vial as the light-sensitive object, not the powder. That is where the somatropin data says the exposure matters, and it is the stage most handling protocols leave unaddressed.
And shorten the interval you do not control. Material shipped same-day from our Santa Barbara facility spends days rather than weeks in transit, in a carton, in a truck — rather than sitting in an international consolidation warehouse under fluorescent light for an unspecified period. That is not a photostability claim, and it should not be read as one. It is simply the one segment of the material’s light history that a domestic purchaser can actually bound.
Everything else is a measurement nobody in this category has yet published. When a supplier tells you a peptide is light stable, the fair question is which option, how many lux hours, and where is the dark control.
References
- International Council for Harmonisation. Q1B — Photostability Testing of New Drug Substances and Products. Step 4 version, 6 November 1996. Option 1 and Option 2 light sources; 1.2 million lux hours and 200 watt hours per square meter; dark controls; quinine chemical actinometry; forced degradation versus confirmatory studies; immediate-pack and marketing-pack sequence.
- International Council for Harmonisation. Q1A(R2) — Stability Testing of New Drug Substances and Products. Step 4 version, 6 February 2003. Photolysis within the stress testing provisions.
- Hipper E, Blech M, Hinderberger D, Garidel P, Kaiser W — photo-oxidation of therapeutic protein formulations: from radical formation to analytical techniques. Pharmaceutics, 2022; 14(1):72. DOI 10.3390/pharmaceutics14010072.
- Pritts JD, Ortega-Rodriguez U, Rao VA — physicochemical differences observed in photostability studies of lyophilized, reconstituted, and diluted somatropin. Pharmaceutical Research, 2025; 43(1):185–193. DOI 10.1007/s11095-025-03986-1.
- Janga KY, King T, Ji N, Sarabu S, Shadambikar G, Sawant S, Xu P, Repka MA, Murthy SN — photostability issues in pharmaceutical dosage forms and photostabilization. AAPS PharmSciTech, 2018; 19(1):48–59. DOI 10.1208/s12249-017-0869-z. Cited at framework level.
- Maple Research Labs batch certificate DBAV-GHK-Cu-50-062226, lot 5816, issued by Testides Analytical; read directly from the certificate linked on the product page.
All materials supplied by Maple Research Labs are provided for research use only. They are not for human use, not for veterinary use, and not for diagnostic or therapeutic application. Nothing in this article describes administration to people.